Download PDF
Thromb Haemost 1967; 18(03/04): 425-432
DOI: 10.1055/s-0038-1655051
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Uroplastin, Its Nature and Its Excretion Pattern in Health and in Certain Disease States

H Joist M. D.   *
1   Department of Internal Medicine, Washington University, St. Louis, Missouri
,
Norma Alkjaersig Ph. D.
1   Department of Internal Medicine, Washington University, St. Louis, Missouri
› Author AffiliationsThis work was supported by grants from The National Institutes of Health, Bethesda, Md. H-3745 and TI-AM 5312.
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

Experimental studies with a partially purified, potent procoagulant from human urine are reported. The material having the electrophoretic property of a â-globulin appears to functionally closely resemble tissue thromboplastin. A significant difference in the excretion of this pro coagulant between normal males and females and deviations from the normal excretion pattern in patients with impaired kidney function and certain other disease states are demonstrated. Possible pathophysiological implications of these findings are discussed.

* Research Fellow in Enzymology. Present address: Medizinische Universitätsklinik Cologne, Germany.


 

  • References

  • 1 Grunke W. Studien über die Blutgerinnung mit besonderer Berücksichtigung der Hämophilie. I. Mitteilung. Einfluß des Harnes auf die Gerinnung hämophilen Blutes. Z. ges. exp. Med. 96: 512 1935;
    CrossrefPubMedGoogle Scholar
  • 2 Tocantins L. M, Lindquist J. N. Thromboplastic activity of the urine. Fed. Proc. 06: 215 1947;
    PubMedGoogle Scholar
  • 3 von Kaulla K. N. Methods for preparation of purified human thromboplastin and fibrinolysokinase from urine. Actahaemat. (Basel) 16: 315 1956;
    PubMedGoogle Scholar
  • 4 Caldwell M. J, von Kaulla K. N, von Kaula E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg) 09: 53 1963;
    PubMedGoogle Scholar
  • 5 von Kaulla K. N, von Kaulla E. Inactivation of pathological inhibitors of intrinsic thromboplastin by procoagulant from human urine. Acta haemat. (Basel) 30: 25 1963;
    CrossrefPubMedGoogle Scholar
  • 6 AoTci N, v. Kaulla K. N. The procoagulant in human urine: Purification, assay and some biochemical and physiological properties. Thrombos. Diathes. haemorrh. (Stuttg) 16: 586 1966;
    PubMedGoogle Scholar
  • 7 Alkjaersig N, Fletcher A. P, Sherry S. The assay of urokinase preparations for contamination with thromboplastic moieties. J. Lab. clin. Med. 65: 732 1965;
    PubMedGoogle Scholar
  • 8 Smyrnoitis F. E, Fletcher A. P, Alkjaersig N, Sherry S. Urokinase excretion in health and its alteration in certain disease states. Thrombos. Diathes. haemorrh. (Stuttg) 03: 257 1959;
    PubMedGoogle Scholar
  • 9 Smithies O. An improved procedure for starch gel electrophoresis: further variations in the serum proteins of normal individuals. Biochem. J. 71: 585 1959;
    CrossrefPubMedGoogle Scholar
  • 10 Bachmann F, Duckert F, Koller F. The Stuart factor assay and its clinical significance. Thrombos. Diathes. haemorrh. 02: 24 1958; (Stuttg.).
    PubMedGoogle Scholar
  • 11 Ferguson J. H. Thromboplastic enzymes. Fed. Proc. 23: 762 1964;
    PubMedGoogle Scholar
  • 12 Matsumura T, von Kaulla K. N. Reduced excretion of urinary procoagulant in uremic patients. Experientia (Basel) 22: 318 1966;
    CrossrefPubMedGoogle Scholar